MaxCyte Inc reports results for the quarter ended March 31 - Earnings Summary

• MaxCyte Inc MXCT.OQ reported a quarterly adjusted loss of 10 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -9 cents. The mean expectation of five analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -12 cents to -10 cents per share.

• Revenue fell 8.4% to $10.39 million from a year ago; analysts expected $9.68 million.

• MaxCyte Inc's reported EPS for the quarter was a loss of 10 cents​.

• The company reported a quarterly loss of $10.26 million.

• MaxCyte Inc shares had risen by 0.4% this quarter and lost 34.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "strong buy"

• Wall Street's median 12-month price target for MaxCyte Inc is $7.00

This summary was machine generated from LSEG data May 8 at 06:39 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)